Clinical Trial Search

Primary: Participants With Complete Remission (CR) at 24 Months — 3 Participants

Primary: Change in Gene Expression Post Chemo — 30; 50 Percent change in cells

Primary: Participants With Objective Response — 0; 1; 13 Participants

Primary: Best Response — 20; 3; 3 Participants

Primary: Response Rate — 0; 1; 3; 11 Participants

Primary: Progression-free Survival (PFS) — 981.0; 1212.0 Days — p=<.0001

Primary: Overall Participant Response Rate: Percentage of Participants With Complete + Partial Response According to Revised National Cancer Institute-sponsored Working Group…

Primary: Progression-free Survival (PFS) — 16.5; 11.1 Months — p=<0.0001

Primary: Improvement in Quality of Remission: Number of Participants With Response Versus No Response by NCI Working Group Criteria Disease Status Change at Start/End of…

Primary: Number of Participants With Complete Remission (CR) — 185 Participants

Primary: Progression-free Survival (PFS) — 15.7; 28.9 months — p=<0.0001

Primary: Number of Participants With Complete Response of the Combination of Ibrutinib, Fludarabine, and Pembrolizumab in Patients With High-risk and/or Relapsed/Refractory…

Primary: Progression-free Survival (PFS) — 31.1; 11.1 Months — p=<0.0001

Primary: Number of Participants With Treatment Emergent Adverse Events (AEs) — 116; 11 Participants

Primary: Number of Patients in Overall Response Categories — 3; 1; 10; 30 Participants

Primary: Number of Patients With Complete Response (CR) — 11 Participants

Primary: Number of Participants With Complete Response (CR) — 14 participants

Primary: Overall Participant Response — 44; 1; 10 Participants

Primary: Number of Patients With Confirmed Objective Status of Complete Response (CR), Complete Clinical Response (CCR), Nodular Partial Response (nPR), or Partial Response (PR)…

Primary: Overall Response Rate (ORR) — 25 Participants

Primary: Treatment Success and Feasibility of Autologous Activated T-cells Infusion, Determined by Number of Participants That Achieved Target-Activated T-cell Dose Without DLT…

Primary: Progression-Free Survival (PFS) as Assessed Using Kaplan-Meier Estimate — 50.6; 33.7 months

Primary: Progression Free Survival (PFS) Based on Investigator Assessment — 106.9; 15.0 months — p=< 0.0001

Primary: Response Rate [Complete Remission (CR) +Complete Remission / Incomplete (CRi) + Nodular Partial Remission (nPR) + Partial Remission (PR)] Based on International Workshop…

Primary: Overall Response Rate — 77.8 % of participants with response by PI

Primary: Overall Response Rate (ORR) — 39 participants

Primary: Complete Response (CR) — 8.3 Percentage of participants with CR — p=0.014

Primary: Number of Participants With an Overall Response — 23; 3; 26 Participants

Primary: Overall Response Rate — 53 percentage of participants

Primary: Number of Patients With Dose-Limiting Toxicities Adverse Events (DLTs) — 0; 0; 0; 0 Participants